Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction

Renin–angiotensin–aldosterone system inhibitors (RAASi) are known to improve outcomes in patients who have heart failure with reduced ejection fraction (HFrEF). To reduce mortality in these patients, RAASi should be uptitrated to the maximally tolerated dose. However, RAASi may also cause hyperkalem...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosano, Giuseppe MC, Spoletini, Ilaria, Vitale, Cristiana, Agewall, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2019
Materias:
Clinical Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848927/
https://www.ncbi.nlm.nih.gov/pubmed/31768268
http://dx.doi.org/10.15420/cfr.2019.8.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848927/
https://www.ncbi.nlm.nih.gov/pubmed/31768268
http://dx.doi.org/10.15420/cfr.2019.8.2

Ejemplares similares